期刊文献+

1例颅内泛耐药鲍曼不动杆菌感染患者的药学监护 被引量:3

Pharmaceutical Care for 1 Case of Extensively Drug Resistant Acinetobacter Baumannii Infection
下载PDF
导出
摘要 目的探讨泛耐药鲍曼不动杆菌感染患者抗感染药学监护的策略。方法对1例泛耐药鲍曼不动杆菌感染患者的抗感染治疗进行分析运用药代动力学(PK)与药效学(PD)理论,从药物选择、给药剂量、给药间隔等方面优化抗菌药物治疗方案。结果与结论对于泛耐药鲍曼不动杆菌,通过选用有效抗菌药物,加大给药剂量、缩短给药间隔时间等方法加强抗感染治疗,可取得较好疗效。 Objective To probe into the anti-infective pharmaceutical care strategy for pan-resistant acinetobacter baumannii infection.Methods Through analyzing the anti-infective therapy for 1 case of pan-resistant acinetobacter baumannii infection according to PD /PK theoretical guidance,the ways to select effective antibiotic therapeutic scheme were optimized in respect of drug selection,drug dosage,the interval of drug delivery.Results Conclusion It may be a good therapeutic strategy for pan-resistant acinetobacter baumannii infection by selecting effective antibiotic drug /increasing the drug dosage /shorting the interval of drug delivery.
出处 《中国药业》 CAS 2016年第4期101-103,共3页 China Pharmaceuticals
关键词 泛耐药鲍曼不动杆菌感染 抗菌药物 药学监护 pan-resistant acmetobacter baumannii infection antibacterial agents pharmaceutical care
  • 相关文献

参考文献11

  • 1陈佰义,何礼贤,胡必杰,倪语星,邱海波,石岩,施毅,王辉,王明贵,杨毅,张菁,俞云松.中国鲍曼不动杆菌感染诊治与防控专家共识[J].中国医药科学,2012,2(8):3-8. 被引量:509
  • 2Garnacho - Montero J, Amaya - Villar R. Multiresistant Acineto- bacter baumannii infections: epidemiology and management[J] .Curr Opin Infect Dis, 2010,23 (4) :332 -339.
  • 3Lee NY, Wang CL, Chuang YC, et al. Combination carbapenem - sulbactam therapy for critically ill patients with muhidrug - resis- tant Acinetobacter baumannii bacteremia : four case reports and an in vitro combination synergy study [ J ]. Pharmacotherapy, 2007, 27(11) :1 506 - 1 511.
  • 4Killer CR, Sampaio JL, Sinto S, et al. In vitro synergy test of meropen- em and sulbactam against clinical isolates of Acinetobacter bau- mannii [J]. Diagn Microbiol Infect Dis, 2005,52 (4) : 317 - 322.
  • 5Fishbain J, Peleg AY. Treatment of Acinetobacter infections[J]. Clin Infect Dis ,2010,51 ( 1 ) :79 - 84.
  • 6Petrosillo N, Ioannidou E, Falagas ME. Colistin monotherapy vs. combination therapy: evidence from microbiological, animal and clinical studies [J]. Clin Microbiol Infect, 2008,14 (9) : 816 - 827.
  • 7Sopirala MM, Mangino JE, Gebreyes WA, et al. Synergy testing by Etest, microdilution checkerboard, and time- kill methods for pan - drug - resistant Acinetobacter baumannii [J]. Antimicrob A- gents Chemother,2010,54( 11 ) :4 678 - 4 683.
  • 8Entenza JM, Moreillon P. Tigecycline in combination with other an- timicrobials: a review of in vitro, animal and case report studies[J]. Int J Antimicrob Agents ,2009,34 : 8. e1 - 9.
  • 9Petersen PJ, Labthavikul P, Jones CH, et al. In vitro antibacteri- al activities of tigecycline in combination with other antimicro- bial agents determined by chequerboard and time- kill kinetic analysis [J]. J Antimicrob Chemother, 2006,57 ( 3 ) : 573 - 576.
  • 10Neonakis IK, Spandidos DA, Petinaki E. Confronting mul- tidrug - resistant Acinetobacter baumannii : a review [J]. Int J Anti microb Agents, 2011,37 (2) : 102 - 109.

二级参考文献49

共引文献517

同被引文献31

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部